Preferred colony stimulating factory products

Switch to:

Preferred colony stimulating factory products


Our preferred granulocyte-colony stimulating factor (G-CSF) drugs, as of Dec. 1, 2017, will be Granix® and Zarxio®, which are biosimilar products for Neupogen®. Granix and Zarxio will require preauthorization.

Neupogen and Neulasta® will not be preferred drugs and will require preauthorization.

This applies to all your ConnectiCare patients with commercial plans, including employer and individual policies.

As a reminder, all requests for chemotherapy and supportive agents, like Granix and Zarxio, as well as Neupogen and Neulasta, should be submitted to New Century Health (NCH), the care manager for our oncology management program.

If your patient continues to require colony stimulating factor products, such as Neupogen, Neulasta, Granix or Zarxio for treatment after Dec. 1, 2017, please submit preauthorization requests to NCH.

To submit requests:

  • Use the NCH secure website at (log in required), or
  • Call NCH’s Utilization Management Intake department at 1-888-999-7713, between 8 a.m. and 8 p.m. (ET), Monday through Friday.

NCH medical oncologists are available for peer-to-peer discussions on treatment regimens.